Drug
Calcifediol
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Parkinsonism | 21 | 18.7 | 18.8 | signal |
| 2 | Dialysis | 29 | 17.7 | 17.9 | signal |
| 3 | Sopor | 20 | 13.0 | 13.1 | signal |
| 4 | Ischaemic Stroke | 23 | 11.2 | 11.3 | signal |
| 5 | Hypocalcaemia | 23 | 10.6 | 10.7 | signal |
| 6 | Hospice Care | 12 | 10.6 | 10.6 | signal |
| 7 | Clostridium Difficile Colitis | 12 | 9.8 | 9.8 | signal |
| 8 | Toxic Skin Eruption | 11 | 9.4 | 9.5 | signal |
| 9 | Hypercalcaemia | 13 | 9.1 | 9.2 | signal |
| 10 | Thrombotic Microangiopathy | 10 | 8.9 | 9.0 | signal |
| 11 | Iron Deficiency Anaemia | 9 | 8.5 | 8.5 | signal |
| 12 | Hepatotoxicity | 21 | 8.2 | 8.3 | signal |
| 13 | Decreased Activity | 10 | 8.1 | 8.1 | signal |
| 14 | Intestinal Perforation | 10 | 7.7 | 7.7 | signal |
| 15 | Respiratory Tract Infection | 22 | 7.3 | 7.4 | signal |
| 16 | Rhabdomyolysis | 35 | 7.3 | 7.4 | signal |
| 17 | Serotonin Syndrome | 16 | 7.2 | 7.3 | signal |
| 18 | End Stage Renal Disease | 15 | 7.1 | 7.1 | signal |
| 19 | Drug Interaction | 129 | 7.0 | 7.4 | signal |
| 20 | Mitral Valve Incompetence | 9 | 6.9 | 6.9 | signal |
| 21 | Hypomagnesaemia | 11 | 6.9 | 6.9 | signal |
| 22 | Acute Kidney Injury | 116 | 6.6 | 6.9 | signal |
| 23 | Hepatocellular Injury | 10 | 6.1 | 6.1 | signal |
| 24 | Electrolyte Imbalance | 8 | 6.0 | 6.0 | signal |
| 25 | Hyperkalaemia | 24 | 6.0 | 6.0 | signal |
| 26 | Gamma-glutamyltransferase Increased | 15 | 5.9 | 5.9 | signal |
| 27 | Myoclonus | 8 | 5.8 | 5.8 | signal |
| 28 | Glomerular Filtration Rate Decreased | 8 | 5.7 | 5.7 | signal |
| 29 | Psychomotor Hyperactivity | 11 | 5.7 | 5.7 | signal |
| 30 | Hepatic Cytolysis | 8 | 5.7 | 5.7 | signal |
| 31 | Sedation | 17 | 5.7 | 5.7 | signal |
| 32 | Blood Thyroid Stimulating Hormone Increased | 6 | 5.6 | 5.6 | signal |
| 33 | Bronchospasm | 9 | 5.4 | 5.5 | signal |
| 34 | Hepatitis | 16 | 5.4 | 5.4 | signal |
| 35 | Apathy | 9 | 5.4 | 5.4 | signal |
| 36 | Status Epilepticus | 7 | 5.4 | 5.4 | signal |
| 37 | Mucosal Inflammation | 16 | 5.3 | 5.3 | signal |
| 38 | Covid-19 Pneumonia | 7 | 5.1 | 5.1 | signal |
| 39 | Hallucination, Visual | 12 | 5.0 | 5.0 | signal |
| 40 | Leukocytosis | 10 | 4.8 | 4.8 | signal |
| 41 | Ventricular Tachycardia | 9 | 4.7 | 4.7 | signal |
| 42 | Plasma Cell Myeloma | 21 | 4.7 | 4.7 | signal |
| 43 | Tubulointerstitial Nephritis | 10 | 4.6 | 4.6 | signal |
| 44 | Therapy Partial Responder | 8 | 4.6 | 4.6 | signal |
| 45 | Muscle Rigidity | 6 | 4.3 | 4.4 | signal |
| 46 | Cardiac Failure Congestive | 40 | 4.3 | 4.3 | signal |
| 47 | Cytomegalovirus Infection | 8 | 4.2 | 4.2 | signal |
| 48 | Cholestasis | 9 | 4.1 | 4.1 | signal |
| 49 | Toxic Epidermal Necrolysis | 7 | 4.0 | 4.0 | signal |
| 50 | Orthostatic Hypotension | 8 | 4.0 | 4.0 | signal |
| 51 | Ankle Fracture | 7 | 3.9 | 3.9 | signal |
| 52 | Acute Myeloid Leukaemia | 7 | 3.9 | 3.9 | signal |
| 53 | Tachypnoea | 6 | 3.8 | 3.8 | signal |
| 54 | Product Prescribing Issue | 9 | 3.8 | 3.8 | signal |
| 55 | Lactic Acidosis | 14 | 3.8 | 3.8 | signal |
| 56 | Hypoglycaemia | 21 | 3.7 | 3.8 | signal |
| 57 | Pancytopenia | 24 | 3.7 | 3.8 | signal |
| 58 | Cognitive Disorder | 20 | 3.7 | 3.7 | signal |
| 59 | Epilepsy | 13 | 3.7 | 3.7 | signal |
| 60 | Hyperthyroidism | 6 | 3.6 | 3.6 | signal |
| 61 | Spinal Fracture | 8 | 3.5 | 3.5 | signal |
| 62 | Psoriatic Arthropathy | 16 | 3.4 | 3.5 | signal |
| 63 | Tuberculosis | 5 | 3.4 | 3.4 | signal |
| 64 | Angioedema | 17 | 3.3 | 3.4 | signal |
| 65 | Cytokine Release Syndrome | 7 | 3.2 | 3.2 | signal |
| 66 | Osteonecrosis Of Jaw | 9 | 3.1 | 3.1 | signal |
| 67 | Hypertensive Crisis | 4 | 3.1 | 3.1 | no signal |
| 68 | Internal Haemorrhage | 4 | 3.0 | 3.0 | no signal |
| 69 | Hospitalisation | 53 | 3.0 | 3.1 | signal |
| 70 | Eyelid Oedema | 4 | 3.0 | 3.0 | no signal |
| 71 | Haematotoxicity | 3 | 2.8 | 2.8 | no signal |
| 72 | Decreased Immune Responsiveness | 3 | 2.7 | 2.7 | no signal |
| 73 | Pericarditis | 5 | 2.6 | 2.6 | no signal |
| 74 | Incorrect Product Administration Duration | 6 | 2.6 | 2.6 | signal |
| 75 | Device Occlusion | 4 | 2.5 | 2.5 | no signal |
| 76 | Diabetes Mellitus Inadequate Control | 5 | 2.4 | 2.4 | no signal |
| 77 | Myelodysplastic Syndrome | 4 | 2.4 | 2.4 | no signal |
| 78 | Nephropathy Toxic | 3 | 2.3 | 2.3 | no signal |
| 79 | Myocarditis | 3 | 2.3 | 2.3 | no signal |
| 80 | Abnormal Behaviour | 10 | 2.2 | 2.2 | signal |
| 81 | Bone Density Decreased | 6 | 1.6 | 1.6 | no signal |
| 82 | Drug Abuse | 8 | 0.8 | 0.8 | no signal |